2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Dermatologic
1
Conditions
Lung Neoplasms
5
Glioma
3
Glioblastoma
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Head and Neck Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Sarcoma
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Papillary renal cell carcinoma, sporadic
1
Pancreatic Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Osteoradionecrosis
1
Neurotoxicity Syndromes
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hereditary leiomyomatosis and renal cell cancer
1
Hematopoietic and Lymphoid System Neoplasm
1
Healthy Volunteers
1
Interventions
pembrolizumab
300
Nivolumab
273
Ipilimumab
250
aldesleukin
137
Cyclophosphamide
136
Interleukin-2
105
trametinib
82
dabrafenib
76
Temozolomide
75
Dacarbazine
74
Vemurafenib
71
fludarabine
68
fludarabine phosphate
62
Biopsy
49
binimetinib
47
sargramostim
44
Radiosurgery
44
Bevacizumab
43
Paclitaxel
42
encorafenib
40
incomplete Freund's adjuvant
39
atezolizumab
38
Radiotherapy
37
Specimen Handling
36
Cisplatin
36
CTLA-4 Antigen
36
Magnetic Resonance Spectroscopy
35
Carboplatin
35
cobimetinib
34
Introns
33
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Contrast Media
×
Clear all
NCT07492121
2026-03-25
GAPIMET
University of Zurich
Phase 2
Not yet recruiting
180 enrolled